Abstract
Objective: There are few new approaches to the pharmacotherapeutic treatment of methamphetamine dependence in the literature. The publications contain abundant data on various methods of pharmacotherapeutic treatment of methamphetamine dependence. However, no pharmacotherapeutic therapy for methamphetamine dependence is sufficient. Materials and Methods: This was a double-blind study in patients diagnosed with methamphetamine dependence according to DSM-5. A total of 100 patients who met the DSM-5 criteria for methamphetamine dependence were examined. All male patients from 18 to 60 years old. The patients were divided into two groups of 50 people: the first group received clomipramine (anafranil) 300 mg / day (100 mg 3 times a day) and carbamazepine 600 mg / day (200 mg 3 times a day) orally. The second group received an indifferent drug (placebo) Results: as shown by follow-up data (12 months), among 50 patients who received anaphrani and carbamazepine only, 10 had short-term breakdowns associated with exposure to microsocial causes. The rest of the patients were in remission. Among patients receiving placebo, only 5 patients experienced remission, all the rest had cases of relapse. Responder analysis was performed using chi-square (x2) and analysis of variance (ANOVA). Conclusion. Clinical statistics indicate the high efficiency of the use of anaphrani and carbamazepine in the treatment of methamphetamine dependence. The mechanisms of action of the drug are being discussed.
Highlights
According to [1] WORLD DRUG REPORT 2021, methamphetamine continues to dominate the global production of ATS amphetamine-type stimulants (ATS)
Clinical statistics indicate the high efficiency of the use of anaphrani and carbamazepine in the treatment of methamphetamine dependence
Problems of pharmacological treatment to methamphetamine dependence very problematic. This is the first study on the use of anafranil and cabamazepine, randomized, double-blind placebo-controlled study
Summary
According to [1] WORLD DRUG REPORT 2021, methamphetamine continues to dominate the global production of ATS amphetamine-type stimulants (ATS). In the WORLD DRUG REPORT 2021[2] indicated, that the abuse of methamphetamine, a highly addictive and potent stimulant, remains an extremely serious problem in the United States. In some countries, this problem has even reached the point where it is more dangerous than opioids and leads to more crime and violence. According to the 2017 National Survey on Drug Use and Health (NSDUH), more than 14.7 million people (5.4 percent of the population) have tried methamphetamine at least once. [3] write thatNSDUH reports that nearly 1.6 million people used methamphetamine in the year preceding the survey, 1 and remains one of the most frequently abused stimulants in the world Chomchai C, Chomchai S. [3] write thatNSDUH reports that nearly 1.6 million people used methamphetamine in the year preceding the survey, 1 and remains one of the most frequently abused stimulants in the world
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
